Extranodal Ocular Adnexal Marginal Zone Lymphoma in a Ten-Year-Old Child

Nazan Çetingül*, Melis Palamar**, Şükriye Hacıkara*, Serra Kamer***, Hamiyet Hekimci Özdemir*, Eda Ataseven*, Özlem Barut Selver**, Mine Hekimgil****

*Ege University Faculty of Medicine, Department of Child Diseases, İzmir, Turkey
**Ege University Faculty of Medicine, Department of Ophthalmology, İzmir, Turkey
***Ege University Faculty of Medicine, Department of Radiation Oncology, İzmir, Turkey
****Ege University Faculty of Medicine, Department of Pathology, İzmir, Turkey

Abstract
A 10-year-old girl was brought to the clinic with the complaint of a salmon-colored conjunctival lesion for 1 month. With the aid of histopathological evaluation and other tests, extranodal ocular adnexal marginal zone lymphoma was diagnosed. The patient was graded as T1bN0M0 according to AJCC and Stage 1 according to Ann Arbor classification. She was treated with external radiotherapy at 1.8 Gy/day for 17 days for a total dose of 36 Gy. She is in remission for 26 months and still being followed up.

Keywords: Conjunctiva, eye, lymphoma, marginal zone, ocular adnexal lymphoma

Introduction
Lymphomas in the ocular adnexa predominantly result from B-cell proliferation and can arise from the conjunctiva, eyelids, lacrimal glands, and orbit. The most common type of ocular adnexal lymphoma (OAL) is extranodal marginal zone B-cell lymphoma (MZL), which is an extremely rare subtype of non-Hodgkin lymphoma (NHL) in childhood.1,2 Although most NHL in children show aggressive behavior, this rare type tends to be indolent. There are few reported cases of primary ocular adnexal MZL in children.3 OALs have recently been classified according to the American Joint Committee on Cancer (AJCC) staging system with variable prognoses.4

Some infectious agents, immunodeficiency, autoimmunity, genetic mutations and immunosuppression have been linked to MZL and appear to be integral to the etiopathology.5 Retrospective studies documented the use of various treatment modalities such as local surgery alone, local radiotherapy alone, and several chemotherapy, targeted therapy, immunotherapy, or antimicrobial therapies in adult patients. Although local radiation may provide local control in adults, there is no well-established treatment modality for pediatric patients.6

Case Report
A 10-year-old girl presented to the ophthalmology department with a fast-growing salmon-colored mass protruding from the medial aspect of the right lower eyelid for approximately 1 month (Figure 1A). The orbital lesion was also demonstrated on magnetic resonance imaging (MRI) (Figure 1B) and excisional
biopsy of the mass was performed. Histopathological examination revealed B-cell MZL (Figure 2 A, B, C, D, E, F).

Upon diagnosis, the patient was referred to the pediatric oncology department. On physical examination, lymphadenopathy and hepatosplenomegaly were not detected. The metastatic workup including hemogram, biochemistry tests, immunoglobulins, brain MRI, cerebrospinal fluid cytology, and bone marrow study were within normal limits. Autoantibody tests were negative. Helicobacter pylori, Chlamydia psittaci, and Chlamydia trachomatis antibodies were negative. Conjunctival smear was unremarkable. The patient did not have any history of conjunctivitis or exposure to birds. Apart from the lesion in the right eye, no other pathological involvement was detected in PET-CT. The patient was graded as T1bN0M0 according to AJCC and as Stage 1 according to Ann Arbor staging.

As repeated ophthalmological examinations revealed bilateral suspicious follicular reaction, Chlamydia was assumed and antimicrobial treatment (doxycycline, 200 mg/day) was initiated. After 2 weeks of treatment, progression of the tumor was observed, and external radiotherapy was planned immediately. The prescribed dose was 36 Gy in 17 fractions to the isocenter (1.8 Gy/fraction dose) using 6 MeV electrons. Cerrobend block was created to protect the lens. Radiotherapy resulted in rapid remission. The child is currently in remission for 26 months. The patient’s mother consented to all treatments and publication of this article.

Discussion

Pediatric B-cell MZLs are detected in the marginal zone of secondary lymphoid tissues. These lymphomas can occur in lymph organs/nodes (nodal MZL) (15%), spleen (15%), and in nonlymphoid organs such as conjunctiva, lung, skin, stomach, orbit, and dura (extranodal MZL) (70%).1,2,3 Pediatric extranodal MZL is an extremely rare entity, comprising less than 1% of all pediatric lymphomas.1,2,3

Extranodal MZLs that occur in the periorbital region are termed as OAL and often involve several tissues such as conjunctiva, orbit, and eyelid. The incidence of OAL is approximately 0.2 per 100,000 individuals. Most OALs are B-cell NHL belonging to 1 of 5 subtypes: extranodal marginal zone/mucosa-associated lymphoid tissue (MALT) lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and lymphoplasmacytic lymphoma.1 Extranodal MZL/MALT lymphomas are approximately 80% low grade and typically follow an indolent course.

MZL is a relatively common entity in adults (5-17% of all NHL diagnoses). The median age at MALT/MZL diagnosis is approximately 60 years, and few pediatric cases have been reported.2,7 Some chronic infectious agents (H. pylori in gastric extranodal MZL, Chlamydia spp. in ocular adnexal MZL, etc.), immunodeficiency, autoimmunity (Sjögren’s syndrome, Hashimoto’s thyroiditis, and other autoimmune diseases), genetic mutations, and immunosuppression have been reported to be linked to MZL. Chronic inflammation at the affected site certainly plays a major role, with both exogenous and endogenous antigens being potentially responsible for the activation of inflammatory responses in ocular adnexal MZL patients.3 In the present 10-year old patient, H. pylori, Ch. psittaci, and Ch. trachomatis antibodies and all autoimmune tests were negative and conjunctival smear was unremarkable.

Morphologically, extranodal MZL resembles the adult counterparts, and the differential diagnosis includes reactive marginal zone hyperplasia and pediatric follicular lymphoma. These blastic cells from the diagnostic lymphoepithelial lesions are helpful in the morphologic distinction of this lymphoma from reactive lymphoid hyperplasia associated with chronic inflammation such as chronic conjunctivitis. The blastic cells express the common B cell markers such as CD20.8 The present case presented dense small lymphocytic infiltrate with destruction of normal architecture, forming follicular colonization. Immunophenotypically, the neoplastic cells were positive for CD20, CD10, CD23, and CD43, but negative for CD5, CD11a, CD23, BCL6, and cyclin D1. The diagnosis was confirmed by the BCL2 and CD43 expression of neoplastic small lymphocytes, which may further be confirmed by the demonstration of monotypical expression of light chains on the plasma cell component by immunohistochemistry or in-situ hybridization. Unfortunately, the plasma cells were scarce in
achieve prompt diagnosis in suspected cases. Systemic evaluation occur in children. As with adult patients, biopsy is mandatory to months.

radiotherapy and the patient is currently in remission for 26 day for 7 days with a total dose of 36 Gy was performed. No enlarged rapidly. For this reason, external radiotherapy 1.8 Gy/day) was initiated. In the third week of treatment, the tumor was assumed and antimicrobial treatment (doxycycline 200 mg/d) was initiated. In the third week of treatment, the tumor enlarged rapidly. For this reason, external radiotherapy 1.8 Gy/day for 7 days with a total dose of 36 Gy was performed. No complications other than acute erythema were observed due to radiotherapy and the patient is currently in remission for 26 months.

In conclusion, although rare, ocular adnexal MZL may also occur in children. As with adult patients, biopsy is mandatory to achieve prompt diagnosis in suspected cases. Systemic evaluation for additional involvement should also not be neglected.

Ethics
Informed Consent: It was obtained.
Peer-review: Externally and internally peer-reviewed.

Authorship Contributions
Surgical and Medical Practices: M.P., NÇ., S.K., Concept: M.P., NÇ., S.K., Ş.H., H.H.Ö., E.A., M.H., Design: M.P., NÇ., S.K., Ş.H., H.H.Ö., E.A., M.H., Data Collection or Processing: M.P., NÇ., S.K., Ş.H., H.H.Ö., E.A., M.H., Ö.B.S., Analysis or Interpretation: M.P., NÇ., S.K., Ş.H., H.H.Ö., E.A., M.H., Literature Search: M.P., NÇ., S.K., Ş.H., H.H.Ö., E.A., M.H., Writing: M.P., NÇ., S.K., Ş.H., H.H.Ö., E.A., M.H.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References
1. Shields CL, Chien JL, Surakakunchanukul T, Siouti K, Lally SE, Shields JA. Conjunctival Tumors: Review of clinical features, risks, biomarkers, and outcomes- the 2017 Donald M Gass Lecture. Asia-Pacific J Ophthalmol. 2017;6:109-120.
2. Kram DE, Brathwaite CD, Kharib ZA. Bilateral Conjunctival Extranodal Marginal Zone B-cell Lymphoma. Pediatr Blood Cancer. 2010;55:1414-1416.
3. Inciçöz- Özlemir S, Yüksel N, Bozkurt C, Sahin G, Memis L, Dizman A, Ertem U. A rare type of cancer in children: extranodal marginal zone B-cell (MALT) lymphoma of the ocular adnexa. Turk J Pediatr. 2014;56:295-298.
4. Graue GF, Finger PT, Maher E, Della Rocca D, Della Rocca R, Lelli GJ Jr, Milman T. Ocular adnexal lymphoma staging and treatment: American Joint Committee on Cancer versus Ann Arbor. Eur J Ophthalmol. 2013;23:344-355.
5. Foster LH, Portell CA. The role of infectious agents, antibiotics, and antiviral therapy in the treatment of extranodal marginal zone lymphoma. Curr Treat Options Oncol. 2015;16:28.
6. Uno T, Isobe K, Shikama N, Nishikawa A, Oguchi M, Ueno N, Irimaj O, Ohsnshi H, Mikata A, Ito H. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients. Cancer. 2003;98:865-871.
7. Tirmann M, Häring S, Heidemann M, Reichelt J, Claviera A. Mucosa-associated lymphoid tissue lymphomas in the conjunctiva of a child. Virchows Arch. 2004;444:198-201.
8. Taddese-Heath L, Pirlaiga S, Sorensa L, Bussey M, Raffeld M, Jaffe ES. Marginal zone B-cell lymphoma in children and young adults. Am J Surg Pathol. 2003;27:522-531.
9. Tuncer S, Tanlyldiz B, Basaran M, Buyukbahani N, Dogan O. Systemic Rituximab Immunotherapy in the Management of Primary Ocular Adnexal Lymphoma: Single Institution Experience. Curr Eye Res. 2015;40:780-785.
10. Çalış E, Gündüz K, Kuzu I, Erden E. Clinical findings and treatment results in ocular adnexal lymphomas. Turk J Ophthalmol. 2013;43:374-378.
11. Dhakal B, Fenske TS, Ramalingham S, Shiff J, Epperla N, Hasking P, Rein I, Barerjee A, Hari P, D’Souza A, Shah N, Siker M, Grieppentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M. Local disease control in ocular adnexal lymphoproliferative disorders: comparative outcomes of MALT versus non-MALT histologies. Clin Lymphoma Myeloma Leuk. 2017;17:305-311.